Eyenuk, Inc.
EyeArt by Eyenuk is an autonomous, FDA-cleared AI for diabetic retinopathy screening and disease detection at the point of care.
Funding history
About Eyenuk, Inc.
How much funding has Eyenuk, Inc. raised?
Eyenuk, Inc. has raised $5.6M in total funding. The most recent round was Series A.
Where is Eyenuk, Inc. headquartered?
Eyenuk, Inc. is headquartered in Woodland Hills, CA.
What does Eyenuk, Inc. do?
EyeArt by Eyenuk is an autonomous, FDA-cleared AI for diabetic retinopathy screening and disease detection at the point of care.
What problem does Eyenuk, Inc. solve?
Manual screening for diabetic retinopathy can no longer keep pace since 1 in 3 adults with diabetes are affected, even though early detection can prevent 95% of related vision loss.
What's Eyenuk, Inc.'s solution?
Eyenuk's EyeArt platform performs autonomous AI retinal exams that detect diabetic retinopathy in seconds at the point of care, without needing a specialist or (typically) patient dilation.
What makes Eyenuk, Inc. different?
The page states it is the first and only FDA 510(k)-cleared autonomous AI for vision-threatening DR detection, citing 96-97% sensitivity/specificity figures and SOC 2 Type 2, HIPAA, and GDPR compliance.
What makes Eyenuk, Inc. notable?
Founded in 2010 by Kaushal Solanki, the AI-powered eye-screening company has raised over $43M, including a $26M Series A led by AXA IM Alts.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.